stocks logo

ADIL

Adial Pharmaceuticals Inc
$
0.514
+0.034(7.080%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.520
Open
0.4706
VWAP
0.50
Vol
2.43M
Mkt Cap
8.11M
Low
0.4651
Amount
1.21M
EV/EBITDA(TTM)
--
Total Shares
4.23M
EV
5.74M
EV/OCF(TTM)
--
P/S(TTM)
--
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Show More
1 Analyst Rating
up Image
289.11% Upside
Wall Street analysts forecast ADIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image
289.11% Upside
Current: 0.514
sliders
Low
2.00
Averages
2.00
High
2.00
Rodman & Renshaw
Brandon Folkes
Strong Buy
Initiates
$8
2024-11-14
Reason
Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a Buy rating and $8 price target. The firm believes Adial has the potential to outperform over the next 12 months, saying its AD04 is designed to reduce alcohol consumption without the need for inpatient stays. The molecule being explored, ondansetron, is widely used, well-characterized, and has shown promising data to fill a gap where other treatments for alcohol use disorder fall short, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Adial Pharmaceuticals Inc (ADIL.O) is -0.78, compared to its 5-year average forward P/E of -1.79. For a more detailed relative valuation and DCF analysis to assess Adial Pharmaceuticals Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.79
Current PE
-0.78
Overvalued PE
-0.41
Undervalued PE
-3.17

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.76
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.86
Undervalued EV/EBITDA
-2.38

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
21509.22
Current PS
0.00
Overvalued PS
98863.25
Undervalued PS
-55844.82

Financials

Annual
Quarterly
FY2025Q1
YoY :
+22.89%
-2.27M
Operating Profit
FY2025Q1
YoY :
-65.59%
-2.23M
Net Income after Tax
FY2025Q1
YoY :
-84.47%
-0.34
EPS - Diluted
FY2025Q1
-1.59M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ADIL News & Events

Events Timeline

2025-07-16 (ET)
2025-07-16
08:36:33
Adial regains compliance with Nasdaq's Equity Listing requirement
select
2025-07-09 (ET)
2025-07-09
08:37:30
Adial Pharmaceuticals files PCT patent application for core assets
select
2025-06-25 (ET)
2025-06-25
08:39:24
Adial Pharmaceuticals secures U.S.-based manufacturing through agreements
select
Sign Up For More Events

News

3.5
07-09Yahoo Finance
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck
9.0
06-26NASDAQ.COM
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
9.5
06-26Benzinga
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Sign Up For More News

FAQ

arrow icon

What is Adial Pharmaceuticals Inc (ADIL) stock price today?

The current price of ADIL is 0.514 USD — it has increased 7.08 % in the last trading day.

arrow icon

What is Adial Pharmaceuticals Inc (ADIL)'s business?

arrow icon

What is the price predicton of ADIL Stock?

arrow icon

What is Adial Pharmaceuticals Inc (ADIL)'s revenue for the last quarter?

arrow icon

What is Adial Pharmaceuticals Inc (ADIL)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Adial Pharmaceuticals Inc (ADIL)'s fundamentals?

arrow icon

How many employees does Adial Pharmaceuticals Inc (ADIL). have?

arrow icon

What is Adial Pharmaceuticals Inc (ADIL) market cap?